Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 17 Oct 2017 Planned primary completion date changed from 15 Oct 2017 to 30 Oct 2017.
- 03 Oct 2017 Planned primary completion date changed from 29 Sep 2017 to 15 Oct 2017.
- 18 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 29 Sep 2017.